Insider Buying: Indivior (NASDAQ:INDV) CAO Acquires $54,420.00 in Stock

Indivior PLC (NASDAQ:INDV) CAO Woodrow Anderson acquired 1,500 shares of Indivior stock in a transaction dated Wednesday, August 5th. The shares were purchased at an average cost of $36.28 per share, with a total value of $54,420.00. Following the completion of the transaction, the chief accounting officer directly owned 26,138 shares of the company’s stock, valued at $948,286.64. This trade represents a 6.09% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Indivior Stock Performance

NASDAQ INDV opened at $38.82 on Friday. The stock has a market capitalization of $4.58 billion, a price-to-earnings ratio of 13.91 and a beta of 0.86. The stock’s 50 day moving average price is $39.28 and its two-hundred day moving average price is $35.64. Indivior PLC has a 52 week low of $21.83 and a 52 week high of $42.81.

Indivior (NASDAQ:INDV) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $5.75 earnings per share for the quarter. Indivior had a net margin of 26.65% and a negative return on equity of 283.11%. The company had revenue of $343.00 million during the quarter. On average, equities research analysts forecast that Indivior PLC will post 3.66 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on INDV. Barclays decreased their target price on shares of Indivior from $46.00 to $43.00 and set an “overweight” rating for the company in a research report on Wednesday. Craig Hallum restated a “buy” rating and set a $53.00 price objective on shares of Indivior in a research note on Tuesday. Zacks Research cut Indivior from a “strong-buy” rating to a “hold” rating in a report on Monday, June 29th. Finally, Weiss Ratings raised Indivior from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, July 24th. Five equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Indivior currently has an average rating of “Moderate Buy” and a consensus price target of $45.17.

Hedge Funds Weigh In On Indivior

Several hedge funds and other institutional investors have recently made changes to their positions in INDV. Salomon & Ludwin LLC acquired a new position in Indivior during the fourth quarter worth $30,000. Harbor Capital Advisors Inc. lifted its stake in Indivior by 309.9% in the fourth quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock valued at $37,000 after acquiring an additional 781 shares during the last quarter. Quarry LP bought a new position in shares of Indivior in the 3rd quarter valued at about $26,000. Caitong International Asset Management Co. Ltd grew its position in shares of Indivior by 72.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock valued at $39,000 after acquiring an additional 460 shares during the period. Finally, Rockefeller Capital Management L.P. increased its stake in shares of Indivior by 512.4% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock worth $46,000 after purchasing an additional 1,076 shares during the last quarter. 60.33% of the stock is owned by institutional investors.

Indivior News Summary

Here are the key news stories impacting Indivior this week:

• Positive Sentiment: HC Wainwright raised its Indivior earnings forecasts across 2026–2030. The firm lifted its 2026 EPS estimate to $3.66 from $3.08, raised 2027 EPS to $3.83 from $3.34, and increased 2028–2030 estimates to $3.99, $4.22 and $4.46, respectively. Its quarterly estimates also rose to $0.93 for Q3 2026 and $1.07 for Q4, signaling improved expectations for the company’s operating performance. Indivior analyst estimates
• Positive Sentiment: An insider purchased additional shares. Chief Accounting Officer Woodrow Anderson bought 1,500 shares at an average price of $36.28, increasing his direct holdings by 6.09%. Insider buying can be viewed as a modest vote of confidence in the stock’s valuation and outlook. Insider Buying: Indivior CAO Acquires 1,500 Shares
• Neutral Sentiment: Analyst sentiment remains favorable but not uniformly bullish. Indivior has a consensus “Moderate Buy” rating and an average price target of $45.17, while individual recommendations include a $53.00 buy target from Craig Hallum and a reduced—but still “overweight”—$43.00 target from Barclays. Indivior receives Moderate Buy rating
• Negative Sentiment: A law firm is investigating the proposed Supernus acquisition. Kahn Swick & Foti is reviewing whether the transaction’s price and sale process adequately protect Supernus shareholders. Under the proposed deal, Supernus investors would receive 1.5401 Indivior shares per Supernus share. The investigation may add legal and execution uncertainty to the transaction and could raise concerns about potential share issuance and dilution for Indivior investors. Supernus Pharmaceuticals investor alert

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.